These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 28094469

  • 1. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M.
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 5. Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
    Ueberberg S, Jütte H, Uhl W, Schmidt W, Nauck M, Montanya E, Tannapfel A, Meier J.
    Diabetes Obes Metab; 2016 Dec 29; 18(12):1253-1262. PubMed ID: 27545110
    [Abstract] [Full Text] [Related]

  • 6. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA, Bergmann NC, Knop FK.
    Diabetes Obes Metab; 2016 Sep 29; 18(9):847-54. PubMed ID: 27160961
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R, Almutairi M, Ussher JR.
    Peptides; 2018 Feb 29; 100():94-100. PubMed ID: 29412838
    [Abstract] [Full Text] [Related]

  • 8. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
    Valverde I, Wang GS, Burghardt K, Kauri LM, Redondo A, Acitores A, Villanueva-Peñacarrillo ML, Courtois P, Sener A, Cancelas J, Malaisse WJ, Scott FW.
    Endocrine; 2004 Feb 29; 23(1):77-84. PubMed ID: 15034199
    [Abstract] [Full Text] [Related]

  • 9. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S, Matsui T.
    Curr Pharm Des; 2011 Dec 29; 17(38):4379-85. PubMed ID: 22204436
    [Abstract] [Full Text] [Related]

  • 10. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J.
    Med Clin (Barc); 2014 Dec 29; 143 Suppl 2():8-11. PubMed ID: 25326837
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T.
    Diabetes Obes Metab; 2009 Dec 29; 11 Suppl 3():11-8. PubMed ID: 19878257
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.
    Hou Y, Ernst SA, Heidenreich K, Williams JA.
    Am J Physiol Gastrointest Liver Physiol; 2016 Jan 01; 310(1):G26-33. PubMed ID: 26542397
    [Abstract] [Full Text] [Related]

  • 15. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL.
    Endocr Rev; 2007 Apr 01; 28(2):187-218. PubMed ID: 17353295
    [Abstract] [Full Text] [Related]

  • 16. Incretins and Their Endocrine and Metabolic Functions.
    Seufert J.
    Endocr Dev; 2017 Apr 01; 32():38-48. PubMed ID: 28873383
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF.
    Diabetes Obes Metab; 2007 Sep 01; 9 Suppl 1():23-31. PubMed ID: 17877544
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.